References
- Harrow M, Goldberg JF, Grossman LS, Meltzer HY: Outcome in manic disorders. a naturalistic follow-up study. Arch Gen Psychiatry 1990; 47:665–671
- O–Connell RA, Mayo JA, Flatow L, Cuthbertson B, O–Brien BE: Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991; 159:123–129
- Keck PE Jr, McElroy SL: Outcome in the pharmacologic treatment of bipolar disorder. J Clin Psychopharmacol 1996; 16(2 suppl 1):15S–23S
- Ketter TA, Kalali AH, Weisler RH, for the SPD417 Study Group: A 6-month, multicenter, open-label evaluation of extendedrelease carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65:668–673
- Hoppener RJ, Kuyer A, Meijer JW, Hulsman J: Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980; 21:341–350
- Tomson T: Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol 1984; 41:830–834
- Riva R, Albani F, Ambrosetto G, et al: Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia 1984; 25:476–481
- Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73:159–171
- Baldessarini RJ, Tohen M, Tondo L: Maintenance treatment in bipolar disorder. Arch Gen Psychiatry 2000; 57:490–492